Is Diabetes Hereditary, and What to Do about It

If a close relative — a parent, brother or sister — has type 2 diabetes, the risk of developing the disease is 2.7 times higher than in people with no such cases in the family (Scott RA et al., Diabetologia, 2013). However, what is mostly inherited is not the disease itself but a genetic predisposition to it. The type of diabetes matters, because type 1 and type 2 diabetes have different mechanisms of genetic predisposition. For this reason, hereditary risk estimates for relatives of a person with type 1 diabetes cannot be applied to type 2 diabetes, and vice versa.
From the Apixmed team:
This material was prepared in support of World Diabetes Day and to draw attention to modern methods of disease prevention and a conscious attitude toward health.
What genetic predisposition to diabetes is
Genetic predisposition to diabetes mellitus is a set of DNA variants that, together with other factors — age, body weight, diet and physical activity level — influence the likelihood of developing the disease. Genetic predisposition does not determine whether the disease will develop. It describes how closely a person's genetic profile is associated with diabetes risk compared with other people in the studied population.
This is seen most clearly in twin studies. Identical twins have identical genomes, while fraternal twins share about 50% of their genetic variants, like ordinary siblings. Comparing these pairs helps researchers estimate the contribution of genetics to the development of a particular disease. If one twin has type 1 diabetes, the probability that the other will develop it is over 50% for identical pairs and about 8% for fraternal pairs (Luckett AM et al., Diabetologia, 2023). Thus, genetics plays a major role, but even with an identical genome, type 1 diabetes does not always develop in both twins.
Moreover, genetic predisposition depends directly on the type of diabetes: type 2 diabetes, type 1 diabetes and monogenic diabetes (neonatal diabetes and MODY, maturity-onset diabetes of the young) have very different genetic bases.
How different types of diabetes mellitus are inherited
Type 2 diabetes accounts for 90–95% of all diabetes cases (American Diabetes Association, Standards of Care in Diabetes, 2026). Genetic predisposition is determined by a large number of DNA variants, each of which has only a small effect on disease risk. The largest analysis to date included 2,535,601 people, of whom 428,452 had type 2 diabetes, and identified 1,289 independent signals in 611 regions of the genome (Suzuki K et al., Nature, 2024). Importantly, scientists did not find a single “diabetes gene”: the study confirmed that genetic risk is determined by the combined effect of many genetic variants.
Type 1 diabetes accounts for 5–10% of diabetes cases (ADA, 2026). It is an autoimmune condition, and its genetics works differently. More than 70 regions of the genome are associated with its risk, but over half of the heritability comes from a single region — HLA class II, which affects how the immune system distinguishes “self” from “non-self” (Luckett AM et al., Diabetologia, 2023).
Monogenic diabetes (including neonatal diabetes and MODY) occurs in less than 1–5% of all cases (ADA, 2026). In this case, the disease is caused by a pathogenic variant in a single gene. In most cases of MODY, the affected genes are HNF1A, GCK, HNF4A or HNF1B; in the UK UNITED study, 74% of known MODY cases were caused by variants in HNF1A, HNF4A or GCK (Misra S et al., Current Diabetes Reports, 2018). MODY is inherited in an autosomal dominant manner, so diabetes may be traced through several generations of a family. It should be suspected if diabetes was diagnosed in the first six months of life, or if it appears in successive generations and has an atypical course. In that case, what is needed is not an assessment of predisposition but targeted genetic testing: confirmed monogenic diabetes may change the approach to treatment, and it is the physician who decides whether such a change is needed (ADA, 2026).
Only in monogenic diabetes is a specific pathogenic variant inherited that causes the monogenic form of diabetes. In type 1 and type 2 diabetes, what is inherited is a set of genetic predisposition factors.

Type 1 and type 2 diabetes risk by family history
Type 1 diabetes
Studies give direct risk estimates depending on who is affected (Luckett AM et al., Diabetologia, 2023):
- identical twin — over 50%
- fraternal twin — about 8%
- brother or sister — 6–10%
- child of an affected father — 6–9%
- child of an affected mother — 1–4%.
The risk for a child is higher if the father, rather than the mother, has the disease. The authors link this to a relative maternal protection, but the reason cannot yet be clearly explained.
Type 2 diabetes
Here, researchers usually report not a percentage but a hazard ratio — how many times more often diabetes developed during follow-up. In the European EPIC-InterAct study (Scott RA et al., Diabetologia, 2013):
- a father, mother, brother or sister is affected — risk is 2.7 times higher (HR 2.72; 95% CI 2.48–2.99)
- both parents are affected — 5.1 times higher (HR 5.14; 95% CI 3.74–7.07).
The EPIC-InterAct study did not assess the effect of each type of family relationship separately. That was assessed in the Taiwan Biobank study, which included 111,899 unrelated people whose data were linked to the national health registry. The strongest association with type 2 diabetes was with the disease in a brother or sister (Liao W-L et al., Diabetes, 2026). Note that this is an East Asian sample, so for Ukrainians these results should be treated as a guide rather than an exact measure.
The same EPIC-InterAct study also tested the role of genes: a genetic score of 35 variants explained only about 2% of the risk conferred by family history. Thus, family history and polygenic risk score reflect different aspects of disease predisposition.
Family history and genetic predisposition to diabetes
Family history is the most accessible way to assess risk: it costs nothing and reflects not only genes but also shared diet, family habits and environment. That is why, together with age and weight, it underlies the standard risk scores for type 2 diabetes (Prasad RB et al., Diabetologia, 2025). However, it shows only who in the family is affected, not which risk variants a specific person has inherited. This is clearly seen in type 1 diabetes: although a father and a mother are equally close relatives for a child, the child's risk differs depending on which of them has diabetes. Identical and fraternal twins also look the same on a family tree, yet their risk differs at least sixfold. Drawing up a family tree alone is not enough to explain these differences.
Polygenic risk score and family history in type 2 diabetes
A polygenic risk score (PRS) helps supplement the information from family history: it accounts for the combined effect of many genetic variants and shows how much a person's genetic risk differs from that of a reference population.
This was tested for type 2 diabetes in 431,658 UK Biobank participants, of whom 17,259 developed the disease during follow-up (median 12.5 years). People with no family history of diabetes who were in the top 20% of polygenic risk scores had about the same risk as people with a family history of diabetes and a middle (third) score category. Among those with a normal body mass index (BMI), the highest quintile meant more than twice the risk of type 2 diabetes compared with the middle one (Liu X et al., Journal of the Endocrine Society, 2023). This does not contradict the EPIC-InterAct result: that study examined whether genes explain the risk conferred by family history, while this one examined whether they identify those whom family history misses.
One reason family history may fail to reveal elevated genetic risk is incomplete information about relatives' health. Moreover, the absence of diabetes in the family does not always mean low genetic risk: parents may have lived healthier lives, and a child may have inherited genetic variants associated with higher risk (Prasad RB et al., Diabetologia, 2025).
The clinical utility of polygenic risk scores for type 2 diabetes is still being studied. At present, they are inferior to some clinical measures, notably BMI and HbA1c, in predicting the disease. At the same time, genetic information can complement risk assessment in younger people and in people without excess body weight, in whom traditional risk factors have not yet fully appeared. Its distinguishing feature is that genetic variants remain unchanged throughout life, so such an assessment can be informative even before metabolic abnormalities appear.
Genetic assessment of type 1 diabetes risk
For type 1 diabetes, the clinical use of genetic information has a different character. The ADA recommends offering islet autoantibody screening to people with a family history of type 1 diabetes or a known elevated genetic risk. In adults with additional risk factors, such as a high genetic score, annual repeat testing may be appropriate instead of an interval of once every three years (ADA, 2026).
How the Apixmed Prism genetic test helps assess diabetes risk
Apixmed Prism genotypes about 700,000 genetic markers from a saliva sample, which is analyzed in a partner laboratory in the EU. The “Glucose and Metabolic Syndrome” DNA test covers 51 indicators in nine subgroups: 36 composite indicators assessed using polygenic risk scores, and 15 individual genetic variants in 15 genes. These include genetic predispositions related to fasting glucose, glycated hemoglobin, insulin secretion and sensitivity, prediabetes, type 1 and type 2 diabetes, body composition traits and metabolic syndrome.
The genetic report from the glucose and metabolic syndrome DNA test is not a diagnosis and not a substitute for a medical consultation. The test does not measure current blood glucose or insulin levels. Fasting glucose and HbA1c reflect the state of carbohydrate metabolism, while genetic information supplements this assessment with data on individual predisposition. It may be an additional reason to discuss with a doctor whether preventive checkups are needed and how often. Decisions about necessary tests and further preventive measures should be made together with a doctor.
For more on the link between insulin sensitivity and genetics, see Insulin Sensitivity and Type 2 Diabetes Risk: The Genetic Dimension.

Якщо є спадкова схильність до діабету
Діабет 2 типу
У дослідженні Diabetes Prevention Program (DPP) серед дорослих із предіабетом інтенсивна програма зміни способу життя знизила відносний ризик розвитку діабету 2 типу на 58 %, а застосування метформіну — на 31 % порівняно з плацебо (Knowler WC et al., Lancet Diabetes & Endocrinology, 2025). Учасників випадково розподілили на три групи й спостерігали в середньому 2,8 року. Програма передбачала зниження маси тіла на 5–7 % і щонайменше 150 хвилин фізичної активності на тиждень. За 21 рік спостереження ефект зберігся, хоч і ослаб: захворюваність нижча на 24 % у групі способу життя та на 17 % у групі метформіну, а медіанний час без діабету подовжився на 3,5 і 2,5 року відповідно (Knowler WC et al., Lancet Diabetes & Endocrinology, 2025).
Чи залежить ця користь від генетики, вивчали окремо. У трьох американських когортах (35 759 учасників) якість раціону й полігенний ризик діяли незалежно: в межах будь-якої категорії генетичного ризику якісніше харчування було пов'язане з майже на 30 % нижчим ризиком діабету 2 типу (Merino J et al., PLoS Medicine, 2022). Це спостережне дослідження, тож воно показує зв'язок, а не доводить причинність. За однакового відносного зниження ризику абсолютна користь профілактичних заходів буде більшою в людей із вищим початковим ризиком. Водночас низький генетичний ризик не скасовує впливу віку, надмірної маси тіла та низької фізичної активності.
Детальніше про те, як харчування й генетика разом впливають на результат, — у статті Чому одна і та сама дієта дає різні результати у різних людей: роль генетики і метаболізму.
Діабет 1 типу
Тут логіка інша: спосіб життя його не спричиняє, і змінами в ньому цей діабет не запобігти. Якщо він є в родині, є сенс обговорити з лікарем аналіз на аутоантитіла й знати класичні ознаки дебюту: сильну спрагу, часте сечовипускання, непояснену втрату ваги. Приблизно половина дітей із діабетом 1 типу потрапляє до лікаря вже з кетоацидозом, тобто ознаки встигають пройти непоміченими (ADA, 2026).
Отже, спадковість — важливий, але не єдиний чинник ризику діабету. Сімейний анамнез допомагає оцінити загальний ризик, генетичне тестування доповнює цю оцінку інформацією про індивідуальну схильність, а лабораторні аналізи дають змогу визначити поточний стан вуглеводного обміну. Сукупність цих даних допомагає вчасно визначити, на що звернути увагу, і спільно з лікарем обрати відповідні заходи.
Детальніше про те, як читати генетичний ризик і чому схильність — не вирок, — у статті Спадкова схильність — це не вирок: як читати генетичний ризик.
Вибирати напрям або проаналізувати повний генетичний профіль → Каталог Apixmed Prism
Результати генетичного тесту — це не діагноз і не заміна консультації лікаря. Звіт Apixmed Prism дає генетичний контекст, який доповнює результати обстежень і допомагає приймати рішення разом із лікарем.
Джерела
- Scott RA, Langenberg C, Sharp SJ, et al. The link between family history and risk of type 2 diabetes is not explained by anthropometric, lifestyle or genetic risk factors: the EPIC-InterAct study. Diabetologia. 2013;56(1):60–69. DOI: 10.1007/s00125-012-2715-x
- Luckett AM, Weedon MN, Hawkes G, Leslie RD, Oram RA, Grant SFA. Utility of genetic risk scores in type 1 diabetes. Diabetologia. 2023;66(9):1589–1600. DOI: 10.1007/s00125-023-05955-y
- American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S27–S49. DOI: 10.2337/dc26-S002
- Suzuki K, Hatzikotoulas K, Southam L, et al. Genetic drivers of heterogeneity in type 2 diabetes pathophysiology. Nature. 2024;627(8003):347–357. DOI: 10.1038/s41586-024-07019-6
- Misra S, Owen KR. Genetics of Monogenic Diabetes: Present Clinical Challenges. Curr Diab Rep. 2018;18(12):141. DOI: 10.1007/s11892-018-1111-4
- Liao W-L, Cheng C-W, Chang Y-W, Lin M-C, Cheng C-F, Tsai S-F, Hsu C-C, Wang S-H. Integrating Polygenic Scores and Family History for Type 2 Diabetes Prediction in an East Asian Population: Insights From the Taiwan Biobank. Diabetes. 2026;75(3):582–590. DOI: 10.2337/db25-0357
- Prasad RB, Hakaste L, Tuomi T. Clinical use of polygenic scores in type 2 diabetes: challenges and possibilities. Diabetologia. 2025;68(7):1361–1374. DOI: 10.1007/s00125-025-06419-1
- Liu X, Collister JA, Clifton L, Hunter DJ, Littlejohns TJ. Polygenic Risk of Prediabetes, Undiagnosed Diabetes, and Incident Type 2 Diabetes Stratified by Diabetes Risk Factors. J Endocr Soc. 2023;7(4):bvad020. DOI: 10.1210/jendso/bvad020
- Knowler WC, Doherty L, Edelstein SL, et al. Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial. Lancet Diabetes Endocrinol. 2025;13(6):469–481. DOI: 10.1016/S2213-8587(25)00022-1
- Merino J, Guasch-Ferré M, Li J, et al. Polygenic scores, diet quality, and type 2 diabetes risk: An observational study among 35,759 adults from 3 US cohorts. PLoS Med. 2022;19(4):e1003972. DOI: 10.1371/journal.pmed.1003972













